Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Metformin could be a treatment for women with pre-eclampsia
Thurs September 23rd - Metformin shows promise as a treatment for preterm pre-eclampsia, a study reveals today. More
AI identifies possible drug combination for brain cancer
Thurs September 23rd - Artificial intelligence-enhanced tools have been used to identify a new combination of drugs that could treat a rare and incurable childhood brain cancer. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Malaria vaccine promise

Wednesday October 19th, 2011

A new malaria vaccine is having some success in reducing rates of the disease among young children, it was announced yesterday.

The vaccine, on trial in Africa, has not succeeded in eliminating disease but has reduced rates of disease by nearly half, researchers reported.

So far some 15,000 children in seven African countries have taken part in the research funded with some 200 million US dollars from the Bill & Melinda Gates Foundation. These included some 6,500 babies and another 8,900 infants.

Results of the trial were revealed at the Foundation's Malaria Forum in Seattle, Washington, USA, and also reported in the New England Journal of Medicine.

The findings come from an analysis of the first year after children were vaccinated. During the research some 8,500 children received a vaccine and 4,300 did not.

Of the vaccinated children, some 149 contracted malaria, a rate of 1.7 per cent. This compared with 116 cases amongst the unvaccinated children - a rate of 2.7 per cent.

The findings reported yesterday related mainly to the 6,000 children over the age of five months - and so far the research does not show vaccination leading to a reduction in death rates. About one per cent of children died from the disease.

Researcher Professor Brian Greenwood, from the London School of Hygiene & Tropical Medicine, UK, said: "The interim results of this trial confirm the efficacy of this vaccine in infants and older children and take it a further step along the road to becoming the first malaria vaccine to be licensed and used in public health programs.

"We now have confirmation of its promise as a potentially valuable tool in malaria control.”

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine October 18 2011 DOI: 10.1056/NEJMoa1102287

Tags: Africa | General Health | North America | UK News | World Health

Printer friendly page Printer friendly page